A study published in the July 2018 issue of The Journal of Emergency Medicine compared the “clinical efficacy of” breath-actuated nebulizer (BAN) “and the metered-dose inhaler (MDI) in treating subjects patients 2 to 17 years of age” with mild to moderate asthma exacerbations. In conducting the study, 890 subjects were given albuterol by MDI or BAN and their outcomes were compared. Upon examining the results, researchers concluded “albuterol therapy by MDI is noninferior to BAN for the treatment of mild to moderate asthma exacerbations in children 2 to 17 years of age.”
To view the abstract for the article, click here.
